Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Hyderabad:  In a ray of hope for HIV patients, particularly for the significant burden in the two-Telugu speaking States of Telangana and Andhra Pradesh, several India pharmaceutical companies have secured green light to manufacture Lenacapavir, a ground-breaking drug, administered as injection just twice a year, offering a promising alternative for management of the disease.

The HIV drug Lenacapavir, originally developed by Gilead Sciences and marketed as Sunlenca, offers a new weapon in the fight against HIV for Indian patients. They will no longer have to worry about the complexities of taking oral pills and the difficulties in adhering to the strict anti-retroviral therapy.

A few days ago, Gilead received USFDA approval for Yeztugo (lenacapavir) for twice-yearly use to reduce the risk of sexually acquired HIV. Gilead has also granted permission to Hyderabad-based Dr Reddy’s Laboratories and Hetero Healthcare, Pune-based Emcure Pharmaceuticals and Mylan, through non-exclusive, royalty-free voluntary licensing agreements.

Dr Ishwar Gilada, the president Emeritus of the AIDS Society of India (ASI), has been quoted by several news agencies on the significance of this development. “The voluntary licenses give hope that the medicine may cost less than 100 US dollars, which is 0.3 percent of the innovator’s cost. India needs to lead from the front for lenacapavir’s equitable and timely distribution at the required scale to prevent HIV transmission and help end AIDS,” he said.

Based on the National AIDS Control Organisation (NACO) data (2021 data), an estimated 24 lakh people are living with HIV in India. In Telangana, there are about 1.3 to 1.5 lakh persons with HIV, while Andhra Pradesh accounts for around 3.2 lakh patients.

An interesting feature of this drug is its twice-yearly injection dosing schedule after the initial oral loading dose. This is a leap forward from daily oral pills that have been a standard for management of HIV for decades.

Sector experts said the generic versions of this drug, to be manufactured by Indian companies, will significantly lower the price of Lenacapavir, ensuring its wider reach among rural and urban populations.

Related Posts

  • Pharma
  • July 8, 2025
  • 17 views
‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

As it turns 3, New American Kid on the Block strikes gold Delhi NCR:  AACI (American Accreditation Commission International) took such giant strides in India in just three years as…

  • Pharma
  • July 5, 2025
  • 199 views
Traditional medicine crucial to achieving global goals of Universal Health Coverage

Global goals like Universal Health Coverage (UHC) can only be met when traditional medicine becomes an essential part of the national health policy and wellness delivery, said Dr. Kashinath Samagandi,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

Traditional medicine crucial to achieving global goals of Universal Health Coverage

Traditional medicine crucial to achieving global goals of Universal Health Coverage

Lupin launches Ipratropium Bromide nasal spray in US

Lupin launches Ipratropium Bromide nasal spray in US

Surgical Robot MantraM, First ‘Badge of Vishwaguru’ is on Triumphal March

Surgical Robot MantraM, First ‘Badge of Vishwaguru’ is on Triumphal March